Tamoxifen

Tamoxifen citrate (Nolvadex, Soltamox) is a selective estrogen receptor modulator (SERM) with antagonist activity at hypothalamic-pituitary and breast-tissue estrogen receptors, plus partial agonist activity at endometrial and bone tissue receptors. The pharmacological profile makes it useful for two distinct AAS-protocol applications: post-cycle HPTA recovery and gynaecomastia treatment.

Mechanism — tissue-selective receptor modulation:

Tamoxifen binds estrogen receptor α (ERα) and ERβ with affinity comparable to estradiol but produces partial agonist or pure antagonist effects depending on tissue context. In hypothalamic and pituitary cells, tamoxifen acts as antagonist — occupying ER without triggering the negative-feedback signal that estradiol normally produces. The result is loss of feedback brake on GnRH pulsing, restored pituitary LH and FSH secretion, and resumption of testicular testosterone synthesis.

In breast tissue, tamoxifen acts as antagonist at ERα — blocking the receptor activation that drives glandular proliferation in gynaecomastia. The blockade is direct and selective; systemic estradiol is unchanged, preserving the bone, cardiovascular, lipid, and CNS estrogen-dependent functions.

The oncology indication (adjuvant therapy for ER-positive breast cancer) uses the same antagonist mechanism at tumour ER.

PCT protocol:

– Standard 4-week protocol: 20 mg/day weeks 1–2, then 10 mg/day weeks 3–4
– Alternative: 40 mg/day × 2 weeks, then 20 mg/day × 2 weeks (front-loaded)
– Timing: start 14 days post-last testosterone enanthate injection; 3–5 days post-last propionate; 21–28 days post-last decanoate
– Total course: 28 days for moderate first cycle; extend to 6 weeks for longer cycles

Gynaecomastia protocol:

– Stage 1 (sensitivity without palpable mass): 20 mg/day × 3–4 weeks, continue 2 weeks past symptom resolution
– Stage 2 (palpable mass <4 weeks old): 40 mg/day × 2 weeks front-load, then 20 mg/day × 2–4 weeks; combine with anastrozole to address underlying E2 driver
– Stage 3 (established gland tissue): tamoxifen 20 mg/day concurrent with letrozole AI front-load

Pharmacokinetics:

Elimination half-life of tamoxifen is approximately 5–7 days. Active metabolites N-desmethyltamoxifen and 4-hydroxytamoxifen (the latter with stronger ER affinity than parent compound) extend the effective duration. Once-daily dosing is adequate; twice-daily provides marginal smoothing without therapeutic benefit.

Tamoxifen is metabolised primarily by CYP3A4 and CYP2D6. CYP2D6 polymorphism produces poor-metaboliser users with reduced 4-hydroxytamoxifen formation and theoretically reduced efficacy; clinical relevance is debated and not a routine consideration in AAS protocol design.

Side-effect profile:

– Visual disturbance: rare retinal effects (cataracts, retinopathy) at high cumulative doses (oncology range, multi-year exposure). Not a concern at AAS-protocol dose and duration.
– Hot flashes via central thermoregulatory effects; mild and self-limited.
– Mood effects (mild depression, irritability) in a subset of users.
– Nausea, occasional GI upset.
– Venous thromboembolism risk: documented in oncology populations on long-term high-dose use; not a clinically observed pattern at PCT dosing in young AAS users without prothrombotic risk factors.
– Hepatotoxicity: rare; not a routine concern.

Tamoxifen vs clomiphene — the cleaner choice:

Clomiphene is a 60:40 racemic mixture of enclomifene (pure antagonist, the therapeutic fraction) and zuclomifene (weak partial agonist with serum half-life exceeding 14 days). The zuclomifene residue accumulates across a 4-week course and produces visual disturbance and “clomid fog” mood effects. Tamoxifen lacks the isomer problem and is the cleaner choice for most users; clomiphene retains a niche where its slightly different pituitary action profile is preferred.